First-Ever Mapping of Cancer Patient’s Genome
- More research is needed before garlic can be touted as a way to lower the risk of some types of cancer, according to a new review of studies on the issue. The review shows that despite some health claims to the contrary, there is not enough credible evidence to link garlic to a lower risk
Full Post: Garlic’s Cancer Benefits Challenged
WEDNESDAY, Nov. 5 (HealthDay News) — In a genetics first, researchers report that they have decoded the complete DNA sequence of a person with acute myelogenous leukemia.
There were some surprises — eight previously unknown mutations, along with two already identified genetic alterations, were associated with the blood cell cancer.
But more importantly, it is now possible to detect individual genetic differences for each case of cancer, said study senior author Richard K. Wilson, director of the Washington University Genome Sequencing Center, in St. Louis.
“We found mutations in genes that make a lot of sense when normal cells become cancer cells,” Wilson explained. “That they seem to be fairly unique to this particular patient says on the one hand that this is a complicated disease. But the complications validate our approach — we have to look at a number of patients to see not only what is different but what they have in common.”
The feat brings the routine use of genomic screens for cancer patients a little closer, one expert said.
“Technically, this is a great achievement,” added Richard Gibbs, director of the Human Genome Sequencing Center at Baylor College of Medicine, in Houston. “This really is a new era, based on genome studies. There is real clinical applicability, and that is what’s remarkable about it.”
The findings were reported in the Nov. 6 issue ofNature.
The Washington University center has already started genetic sequencing of a second person with acute myelogenous leukemia (AML), which Wilson said was chosen in part because “it is a cancer type that is extremely aggressive, with no good cure. We have seen some pretty good treatments for other cancers, but this one lags behind.”
“The second [patient genome] is already in progress,” he said, adding that the examination of the genomes of other patients is already underway.
While it cost millions of dollars and years to complete the first map of a single human genome, in 2003, such feats are now becoming routine because of “a new wave of technologies,” Wilson noted. “It miniaturizes and parallelizes, so we can do lots of things in parallel on one platform. We used to be able to look at 100 DNA sequences per sample. Now we can look at 100 million per sample.”
The genome laid out in theNaturestudy is that of a woman in her 50s who died of AML. The current picture is that mutations that turn a cell cancerous occur in sequence, each one pushing the cell closer to uncontrolled, malignant growth. Nine of the mutations in the woman’s case were found in all tumor cells. The tenth was not present in all, and so it is believed to be the last one that occurred, possibly the tipping point that caused the cancer.
The complexity of the genetic changes linked to this one case of AML should not be viewed as discouraging, Gibbs said. “I don’t think there is reason for pessimism,” he said. “It is complicated, but that doesn’t mean we’re not going to understand it.”
New technology may someday make it possible to perform genome sequencing forallcancer patients who need it, Gibbs said. “In the past, our ability to get the information has been questioned,” he said. “When it was $10 million a shot, that was one thing. If it costs $5,000 or $10,000 per case, there is no argument about getting the information.”
The Baylor center is carrying out similar genome studies for several forms of cancer, Gibbs said, including the brain tumor glioblastoma, lung cancer and pancreatic malignancies. And at Washington University, whole-genome studies are planned for breast and lung cancers, Wilson noted.
More information
The basics of cancer genetics are explained by the U.S. National Cancer Institute.
SOURCES: Richard K. Wilson, Ph.D, director, Washington University Genome Sequencing Center, St. Louis; Richard Gibbs, Ph.D., director, Human Genome Sequencing Center, Baylor College of Medicine, Houston; Nov. 6, 2008,Nature
--------------------------------------------------------------------------------------------Related Posts:
The Cure Our Children Foundation, a nonprofit charitable foundation dedicated to children, announced today that the U.S. Food and Drug Administration (FDA) has approved the Orphan Drug Designation of the foundation’s unique drug product for children with Ewing’s Sarcoma cancer. The efforts to develop this drug were made possible by the generous volunteers and researchers
Full Post: FDA grants orphan drug status to new ‘Trojan Horse’ like Ewing’s Sarcoma drug
--------------------------------------------------------------------------------------------
NEW YORK - Nicotine, whether absorbed by smoking cigarettes or inhaling second-hand smoke, may promote tumor growth and the spread of breast cancer, a study found. Nicotine made breast cancer cells more likely to multiply and migrate in laboratory tests, according to the study published in yesterday’s issue of the journal Cancer Research. Such evidence also
Full Post: Nicotine found to spur breast cancer growth
--------------------------------------------------------------------------------------------
(Ivanhoe Newswire) — Nicotine may play a role in breast tumor development and metastases according to a new study. Researchers at the Beth Israel Deaconess Medical Center in Boston found through a series of tests that nicotine can potentially increase breast cancer cell growth and migration. Breast epithelial-like
Full Post: Nicotine and Breast Cancer
--------------------------------------------------------------------------------------------
- A huge study funded by the National Institutes of Health triples the number of genes linked to lung cancer and points toward new treatments. The study analyzed DNA sequences from 623 genes in tumor samples from 188 patients with lung adenocarcinoma, the most common form of lung cancer. The study turned up 26 genes mutated at
Full Post: Lung Cancer Genes Raise Treatment Hopes
--------------------------------------------------------------------------------------------
WASHINGTON— The Food and Drug Administration said Tuesday it will look into concerns that a prominent toxicologist asked to render an independent verdict on a sensitive consumer safety issue may have a financial conflict-of-interest. But an FDA official said there is no reason to believe that University of Michigan professor Martin Philbert did anything improper. The
Full Post: Questions Arise About Scientist’s Involvement With BPA